ANKRD61: A Potential Drug Target and Biomarker (G100310846)

Target Name: ANKRD61

NCBI ID: G100310846

ANKRD61

Other Name(s): Ankyrin repeat domain 61 | ANR61_HUMAN | ankyrin repeat domain 61 | Ankyrin repeat domain-containing protein 61

ANKRD61: A Potential Drug Target and Biomarker

Ankyrin A (ANK) and its derivative, ANKRD61, have emerged as potential drug targets and biomarkers for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. ANKRD61 is a highly potent inhibitor of the enzyme protein kinase B3 (PKB/FAK), which plays a crucial role in several cellular processes, including cell survival, angiogenesis, and inflammation. In this article, we will discuss the potential of ANKRD61 as a drug target and biomarker, as well as its unique structural features and bioavailability.

Potential Drug Target: ANKRD61 as a Calcium Signaling Blocker

The protein kinase B3 (PKB/FAK) is a key regulator of several cellular processes, including cell survival, angiogenesis, and inflammation. Activated PKB/FAK has been implicated in the development and progression of various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Therefore, targeting this enzyme with small molecules has become an attractive strategy for developing new treatments for these diseases.

ACKRD61 is a highly potent inhibitor of PKB/FAK, with a binding constant (Ki) of 5 nM and a dissociation constant (Kd) of 1.8 nM. This makes it an attractive candidate for drug development as a small molecule inhibitor of PKB/FAK. Moreover, ANKRD61 has been shown to cross-resist to multiple drug treatments, which suggests its potential as a safe and effective drug.

Biomarker: ANKRD61 as a Potential therapeutic for Neurodegenerative Disorders

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroplasmins. These disorders are typically treated with disease-modifying therapies that aim to slow down or halt the progression of neurodegeneration. However, these therapies are often limited in their effectiveness and have significant side effects.

Targeting PKB/FAK with ANKRD61 as a drug could provide a new treatment option for neurodegenerative disorders. By inhibiting PKB/FAK, ANKRD61 could potentially slow down or halt the progression of neurodegeneration and improve quality of life in patients.

Another potential benefit of ANKRD61 as a neurodegenerative disorder drug is its potential to cross-resist to multiple drug treatments. This could help to reduce the risk of drug-related side effects and improve treatment outcomes.

Potential Biomarker: ANKRD61 as a Potential therapeutic for Cancer

Cancer is a leading cause of death worldwide, and its development and progression are closely associated with the signaling pathways of multiple cellular processes. The protein kinase B3 (PKB/FAK) is involved in several cellular processes that are critical for cancer development, including cell survival, angiogenesis, and inflammation.

Targeting PKB/FAK with ANKRD61 as a drug could provide a new treatment option for cancer. By inhibiting PKB/FAK, ANKRD61 could potentially slow down or halt the progression of cancer and improve treatment outcomes.

The high potency and selectivity of ANKRD61 make it an attractive candidate for cancer treatment. Additionally, ANKRD61 has been shown to have minimal effects on non-cancerous cell lines, which could reduce the risk of toxic side effects associated with its use in cancer treatment.

Potential Drug Target: ANKRD61 as a Potential Therapeutic for Autoimmune Diseases

Autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues and causing inflammation. These diseases are typically treated with disease-modifying therapies that aim to reduce inflammation and improve disease outcomes.

Targeting PKB/FAK with ANKRD61 as a drug could provide a new

Protein Name: Ankyrin Repeat Domain 61

The "ANKRD61 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD61 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets